The thrombopoietin receptor agonists (TPO-RAs) are a class of platelet growth factors
commonly used to treat immune thrombocytopenia (ITP). There are three agents that have …

Thrombopoietin receptor agonists (TPO‐RAs) are used to treat immune thrombocytopenia
(ITP), but predicting clinical response to TPO‐RAs before initiation is not possible. To …

The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …

Thrombopoietin (TPO) regulates thrombopoiesis through activation of TPO receptors on the
megakaryocyte cell surface, resulting in increased platelet production. The TPO receptor …

Primary immune thrombocytopenia (ITP) is a bleeding disorder that conventionally has been
treated with steroids or other immunosuppressive treatments. The introduction of …

The pathophysiology, classification, epidemiology, and treatment of immune
thrombocytopenia (ITP) have witnessed great progresses in the last decade and are briefly …

Background and objectives Thrombopoietin receptor agonists (TPO ra) are the only
treatments for immune thrombocytopenia (ITP) for which evidence of efficacy and safety from …

The thrombopoietin receptor agonists (THPO‐RA s), romiplostim and eltrombopag, are
effective and safe in immune thrombocytopenia (ITP). However, the value of their sequential …

Sequential use of the TPO‐RAs romiplostim and eltrombopag in ITP patients failing either
agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics …

The recognition of that patients with Immune Thrombocytopenia (ITP) have functional
thrombopoietin deficiency and decreased platelet production due to immune-mediated …